房建工程地基基础施工关键技术探究

地基处理技术是近年来我国房屋建筑工程施工中一种较常见的施工处理技术,多见于房屋建筑工程中的软土地基施工环节。通过以往的房屋建筑经验,如果直接在软土地基上进行建筑施工,地基区域软土很容易会影响房屋建筑工程的稳定性,所以,在针对这一部分软土区域的施工环节,需要针对拟施工的地基软土区域进行处理,提升其软土的稳定性。到目前,地基处理技术已经在我国房屋建筑工程施工中广泛应用,这一技术应用过程中存在的不足也逐渐凸显,如何针对这一技术的不足予以完善,以此提升地基处理技术对房屋建筑质量的积极影响,成为了现阶段房屋建筑地基基础施工质量提升的重要环节之一。     

Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results

Aims: The EINSTEIN-Extension trial (EINSTEIN-EXT) found that continued treatment with rivaroxaban for an additional 6 or 12 months (vs placebo) after 6–12 months of initial anticoagulation significantly reduced the risk of recurrent venous thromboembolism (VTE) with a small non-significant increased risk of major bleeding (none fatal or in critical site). This study aimed to compare total healthcare cost between rivaroxaban and placebo, based on the EINSTEIN-EXT event rates.

Methods: Total healthcare cost was calculated as the sum of treatment and clinical event costs from a US managed care perspective. Treatment duration and event rates were obtained from the EINSTEIN-EXT study. Adjustment on treatment duration was made by assuming a 10% non-adherence rate. Drug costs were based on wholesale acquisition costs. Cost estimates for clinical events (i.e. recurrent deep vein thrombosis [DVT], recurrent pulmonary embolism, major bleeding, clinically relevant non-major bleeding) were determined from the literature. Results were examined over a ±20% range of each cost component and over 95% confidence intervals (CIs) of event rate differences in deterministic (one-way) and probabilistic sensitivity analyses (PSA).

Results: Total healthcare cost was $1,454 lower for rivaroxaban-treated (vs placebo-treated) patients in the base-case, with a lower clinical event cost fully offsetting drug cost. The cost savings of recurrent DVT alone (–$3,102) was greater than drug cost ($2,723). Total healthcare cost remained lower for rivaroxaban in the majority (73%) of PSA (cost difference [95% CI]?=?–$1,454 [–$2,396, $1,231]).

Limitations: This study was conducted over the 1-year observation period of the EINSTEIN-EXT trial, which limited “real-world” applicability and examination of long-term economic impact. Assumptions on drug and clinical event costs were US-based and, thus, not applicable to other healthcare systems.

Conclusions: Total healthcare costs were estimated to be lower for patients continuing rivaroxaban therapy compared to those receiving placebo in VTE patients who had completed 6–12 months of VTE treatment.     

Operational risk quantified with spectral risk measures: a refined closed-form approximation

The quantification of operational risk has become an important issue as a result of the new capital charges required by the Basel Capital Accord (Basel II) to cover the potential losses of this type of risk. In this paper, we investigate second-order approximation of operational risk quantified with spectral risk measures (OpSRMs) within the theory of second-order regular variation (2RV) and second-order subexponentiality. The result shows that asymptotically two cases (the fast convergence case and the slow convergence) arise depending on the range of the second-order parameter. We also show that the second-order approximation under 2RV is asymptotically equivalent to the slow convergence case. A number of Monte Carlo simulations for a range of empirically relevant frequency and severity distributions are employed to illustrate the performance of our second-order results. The simulation results indicate that our second-order approximations tend to reduce the estimation errors to a great degree, especially for the fast convergence case, and are able to capture the sub-extremal behavior of OpSRMs better than the first-order approximation. Our asymptotic results have implications for the regulation of financial institutions, and may provide further insights into the measurement and management of operational risk.     

Psychometric validation of anti-clot treatment scale and treatment satisfaction questionnaire for medication version II in Japanese patients with atrial fibrillation

Aims: The Anti-Clot Treatment Scale (ACTS) and Treatment Satisfaction Questionnaire for Medication version II (TSQM-II) are validated treatment satisfaction patient-reported outcome (PRO) instruments. The ACTS includes two domains: Burdens and Benefits; the TSQM-II includes four: Effectiveness, Side Effects, Convenience, and Global Satisfaction. Japanese-language versions of the ACTS and TSQM-II have been developed and linguistically validated. This study aimed to assess their psychometric properties in Japanese patients with atrial fibrillation (AF).

Materials and methods: ACTS and TSQM-II data from 534 patients with AF were collected in a Japanese post-marketing surveillance study of a direct oral-anticoagulant, rivaroxaban. Four key psychometric properties, in line with best practice guidelines from the US Food and Drug Administration, were examined using traditional psychometric methods: acceptability, scaling assumptions, reliability (i.e. internal consistency reliability, test-retest reliability), and construct validity (i.e. convergent validity and known groups).

Results: ACTS Burdens and Benefits and TSQM-II Effectiveness, Convenience, and Global Satisfaction scales were found to be acceptable (e.g. item-level missing data at baseline <4%), with all scales having good internal consistency (Cronbach’s alpha > 0.80). test-retest reproducibility intraclass correlation coefficients for the ACTS Burdens and Benefits were 0.59 and 0.65, respectively, and between 0.54–0.61 for the TSQM-II scales. Known-groups validity for the ACTS and TSQM-II was supported by differences in scale scores by positive and negative impact (p?<?0.05). Correlations between the ACTS and TSQM-II (convergent validity) were lower than expected (range r?=?0.09–0.48), but in line with the original ACTS development study.

Limitations: Evaluation of test-retest reproducibility was limited by assessment period, which was longer (3 months) than recommended guidelines (usually up to 2 weeks).

Conclusions: Overall, Japanese versions of ACTS and TSQM-II scales satisfied internal consistency reliability and traditional validity criteria. Our study supports the ACTS and TSQM-II as appropriate PRO instruments to measure satisfaction with anticoagulant treatment in Japanese patients with AF.

Trial registration: NCT01598051, clinicaltrials.gov; registered April 20, 2012.     

Economic interpretations of DEA

Research on productive efficiency at the firm level has developed as an important and active strand of research the last decades, both within operations research, management science and economics. Two apparently different definitions of efficiency are examined, but it is shown that when both estimation methods are based on solving linear programming problems the definitions of efficiency are identical. The purpose of the paper is to give the basic ideas of efficiency analyses using DEA as a tool for researchers not so familiar with efficiency analysis and DEA. The concept of shadow prices is given special attention.     

乡镇企业发展的困境与思路——赤湖镇乡镇企业发展情况调查

乡镇企业自产生以来就为解决农村富余劳动力,促进农村经济的发展与稳定,及国民经济持续、稳定、快速地发展作出了重大的贡献。但是,随着国民经济进一步向纵深方向发展,乡镇企业自身的缺陷日益显露出来,加之国内外竞争环境发生了深刻变化。这势必影响乡镇企业潜力的充分发挥与健康发展。如何挖掘发展潜力正是当务之急。本文旨在剖析制约乡镇企业发展的深层次因素,借鉴成功范例的经验,谋求其的新发展。     

外资并购我国企业的动因及对经济的影响

随着跨国公司在我国并购活动的日益增多，外资并购给中国经济带来了正面和负面双重影响．为了保护我国民族工业，促进我国经济健康持续地发展，应积极稳妥地利用外资并购，趋利弊害，消除负面影响，拉动经济增长。     

以风险协议为框架的化工措施管理机制探索与实践

以西方经济学中的代理理论为基础．建立了一套以风险协议为框架、对化工措施全过程进行控制的管理机制和相应的保证体系，提高了化工措施现场实施的成功率和有效率。     

安徽非公经济发展研究

在当代中国,非公经济发展与改革开放及制度变迁原本是相通的,欠发达地区经济发展的实质就是非公经济的发展;安徽非公经济发展滞后的深层机理在于既定制度格局下的路径依赖。本课题深入分析了既定制度格局影响安徽非公经济发展的机制过程,以此为基础,提出了进一步加快发展的思路和对策。     

收购兼并在上市公司发展战略中的地位和实施策略

本文主要阐述了以下三个方面的问题：（1）公司为何及时从事购并交易；（2）如何使购并活动获得成功；（3）制定中国进行购并行动的战略。